{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:47:52Z","timestamp":1788410872618,"version":"build-2803163510"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40259-025-00754-w","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T23:19:05Z","timestamp":1771370345000},"page":"177-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antibody-Drug Conjugates in Gynecologic Oncology: Advances, Challenges, and Future Directions"],"prefix":"10.1007","volume":"40","author":[{"given":"Taliya","family":"Lantsman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"754_CR1","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo R, Tarantino P, Rich JR, et al. The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov. 2024;14:2089\u2013108. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0708.","journal-title":"Cancer Discov"},{"key":"754_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390772","author":"HC Karpel","year":"2023","unstructured":"Karpel HC, Powell SS, Pothuri B. Antibody\u2013drug conjugates in gynecologic cancer. Am Soc Clin Oncol Educ Book. 2023. https:\/\/doi.org\/10.1200\/EDBK_390772.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"754_CR3","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1007\/s11095-015-1624-3","volume":"32","author":"M Damelin","year":"2015","unstructured":"Damelin M, Zhong W, Myers J, Sapra P. Evolving strategies for target selection for antibody-drug conjugates. Pharm Res. 2015;32:3494\u2013507. https:\/\/doi.org\/10.1007\/s11095-015-1624-3.","journal-title":"Pharm Res"},{"key":"754_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ygyno.2018.07.017","volume":"151","author":"KN Moore","year":"2018","unstructured":"Moore KN, O\u2019Malley DM, Vergote I, et al. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018;151:46\u201352. https:\/\/doi.org\/10.1016\/j.ygyno.2018.07.017.","journal-title":"Gynecol Oncol"},{"key":"754_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of Trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42:47\u201358. https:\/\/doi.org\/10.1200\/JCO.23.02005.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"754_CR6","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","volume":"14","author":"O Ab","year":"2015","unstructured":"Ab O, Whiteman KR, Bartle LM, et al. IMGN853, a folate receptor-\u03b1 (FR\u03b1)\u2013targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FR\u03b1-expressing tumors. Mol Cancer Ther. 2015;14:1605\u201313. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-1095.","journal-title":"Mol Cancer Ther"},{"key":"754_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1924","volume":"34","author":"KN Moore","year":"2023","unstructured":"Moore KN, Philipovskiy A, Harano K, et al. 745MO raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): subgroup analysis of a first-in-human phase I study. Ann Oncol. 2023;34:S510. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1924.","journal-title":"Ann Oncol"},{"key":"754_CR8","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Ann Oncol. 2021;32:746\u201356. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.005.","journal-title":"Ann Oncol"},{"key":"754_CR9","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3390\/molecules22081281","volume":"22","author":"H Chen","year":"2017","unstructured":"Chen H, Lin Z, Arnst KE, et al. Tubulin inhibitor-based antibody-drug conjugates for cancer therapy. Molecules. 2017;22:1281. https:\/\/doi.org\/10.3390\/molecules22081281.","journal-title":"Molecules"},{"key":"754_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","volume":"16","author":"L Conilh","year":"2023","unstructured":"Conilh L, Sadilkova L, Viricel W, Dumontet C. Payload diversification: a key step in the development of antibody\u2013drug conjugates. J Hematol OncolJ Hematol Oncol. 2023;16:3. https:\/\/doi.org\/10.1186\/s13045-022-01397-y.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"754_CR11","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","volume":"17","author":"A Thomas","year":"2016","unstructured":"Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016;17:e254\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(16)30030-4.","journal-title":"Lancet Oncol"},{"key":"754_CR12","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1021\/ja00759a054","volume":"94","author":"SM Kupchan","year":"1972","unstructured":"Kupchan SM, Komoda Y, Court WA, et al. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc. 1972;94:1354\u20136. https:\/\/doi.org\/10.1021\/ja00759a054.","journal-title":"J Am Chem Soc"},{"key":"754_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","volume":"9","author":"K Tsuchikama","year":"2018","unstructured":"Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9:33\u201346. https:\/\/doi.org\/10.1007\/s13238-016-0323-0.","journal-title":"Protein Cell"},{"key":"754_CR14","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/0006-2952(90)90613-p","volume":"39","author":"R Bai","year":"1990","unstructured":"Bai R, Pettit GR, Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol. 1990;39:1941\u20139. https:\/\/doi.org\/10.1016\/0006-2952(90)90613-p.","journal-title":"Biochem Pharmacol"},{"key":"754_CR15","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","volume":"13","author":"Z Wang","year":"2023","unstructured":"Wang Z, Li H, Gou L, et al. Antibody-drug conjugates: recent advances in payloads. Acta Pharm Sin B. 2023;13:4025\u201359. https:\/\/doi.org\/10.1016\/j.apsb.2023.06.015.","journal-title":"Acta Pharm Sin B"},{"key":"754_CR16","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/ph17101338","volume":"17","author":"B Valsasina","year":"2024","unstructured":"Valsasina B, Orsini P, Terenghi C, Ocana A. Present scenario and future landscape of payloads for ADCs: focus on DNA-interacting agents. Pharmaceuticals. 2024;17:1338. https:\/\/doi.org\/10.3390\/ph17101338.","journal-title":"Pharmaceuticals"},{"issue":"8","key":"754_CR17","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1002\/ijc.30870","volume":"141","author":"N Takegawa","year":"2017","unstructured":"Takegawa N, Nonagase Y, Yonesaka K, et al. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer. 2017;141(8):1682\u20139. https:\/\/doi.org\/10.1002\/ijc.30870.","journal-title":"Int J Cancer"},{"key":"754_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody\u2013drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327\u201344. https:\/\/doi.org\/10.1038\/s41571-021-00470-8.","journal-title":"Nat Rev Clin Oncol"},{"key":"754_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1208\/s12248-014-9710-8","volume":"17","author":"JR McCombs","year":"2015","unstructured":"McCombs JR, Owen SC. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J. 2015;17:339\u201351. https:\/\/doi.org\/10.1208\/s12248-014-9710-8.","journal-title":"AAPS J"},{"key":"754_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10555-014-9539-8","volume":"34","author":"IB Vergote","year":"2015","unstructured":"Vergote IB, Marth C, Coleman RL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev. 2015;34:41\u201352. https:\/\/doi.org\/10.1007\/s10555-014-9539-8.","journal-title":"Cancer Metastasis Rev"},{"key":"754_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ddtec.2020.07.002","volume":"37","author":"E Tarcsa","year":"2020","unstructured":"Tarcsa E, Guffroy MR, Falahatpisheh H, et al. Antibody-drug conjugates as targeted therapies: are we there yet? A critical review of the current clinical landscape. Drug Discov Today Technol. 2020;37:13\u201322. https:\/\/doi.org\/10.1016\/j.ddtec.2020.07.002.","journal-title":"Drug Discov Today Technol"},{"key":"754_CR22","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22.01900","volume":"41","author":"UA Matulonis","year":"2023","unstructured":"Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol. 2023;41:2436\u201345. https:\/\/doi.org\/10.1200\/JCO.22.01900.","journal-title":"J Clin Oncol"},{"key":"754_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ijc.2910390306","volume":"39","author":"S Miotti","year":"1987","unstructured":"Miotti S, Canevari S, M\u00e9nard S, et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer. 1987;39:297\u2013303. https:\/\/doi.org\/10.1002\/ijc.2910390306.","journal-title":"Int J Cancer"},{"key":"754_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ijc.2910570719","volume":"8","author":"WA Franklin","year":"1994","unstructured":"Franklin WA, Waintrub M, Edwards D, et al. New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int J Cancer Suppl J Int Cancer Suppl. 1994;8:89\u201395. https:\/\/doi.org\/10.1002\/ijc.2910570719.","journal-title":"Int J Cancer Suppl J Int Cancer Suppl"},{"key":"754_CR25","doi-asserted-by":"publisher","first-page":"414","DOI":"10.18632\/oncotarget.519","volume":"3","author":"DJ O\u2019Shannessy","year":"2012","unstructured":"O\u2019Shannessy DJ, Yu G, Smale R, et al. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget. 2012;3:414\u201325. https:\/\/doi.org\/10.18632\/oncotarget.519.","journal-title":"Oncotarget"},{"key":"754_CR26","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ab.2004.12.026","volume":"338","author":"N Parker","year":"2005","unstructured":"Parker N, Turk MJ, Westrick E, et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005;338:284\u201393. https:\/\/doi.org\/10.1016\/j.ab.2004.12.026.","journal-title":"Anal Biochem"},{"key":"754_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","volume":"147","author":"LP Martin","year":"2017","unstructured":"Martin LP, Konner JA, Moore KN, et al. Characterization of folate receptor alpha (FR\u03b1) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FR\u03b1-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017;147:402\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.015.","journal-title":"Gynecol Oncol"},{"key":"754_CR28","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","volume":"35","author":"KN Moore","year":"2017","unstructured":"Moore KN, Martin LP, O\u2019Malley DM, et al. Safety and activity of Mirvetuximab Soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:1112\u20138. https:\/\/doi.org\/10.1200\/JCO.2016.69.9538.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"754_CR29","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1002\/cncr.30736","volume":"123","author":"KN Moore","year":"2017","unstructured":"Moore KN, Borghaei H, O\u2019Malley DM, et al. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor \u03b1-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017;123:3080\u20137. https:\/\/doi.org\/10.1002\/cncr.30736.","journal-title":"Cancer"},{"key":"754_CR30","doi-asserted-by":"publisher","first-page":"5558","DOI":"10.1200\/jco.2015.33.15_suppl.5558","volume":"33","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, O\u2019Malley DM, Seward SM, et al. Phase 1 study of IMGN853, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors. J Clin Oncol. 2015;33:5558\u20135558. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.5558.","journal-title":"J Clin Oncol"},{"key":"754_CR31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/bcp.15937","volume":"90","author":"Y-P Tu","year":"2024","unstructured":"Tu Y-P, Hanze E, Zhu F, et al. Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-\u03b1 positive ovarian cancer: the antibody\u2013drug conjugate, payload and metabolite. Br J Clin Pharmacol. 2024;90:568\u201381. https:\/\/doi.org\/10.1111\/bcp.15937.","journal-title":"Br J Clin Pharmacol"},{"key":"754_CR32","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1158\/1078-0432.CCR-18-2474","volume":"25","author":"UA Matulonis","year":"2019","unstructured":"Matulonis UA, Birrer MJ, O\u2019Malley DM, et al. Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine. Clin Cancer Res. 2019;25:1727\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2474.","journal-title":"Clin Cancer Res"},{"key":"754_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101155","volume":"47","author":"A Hendershot","year":"2023","unstructured":"Hendershot A, Slabaugh M, Riaz KM, et al. Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. Gynecol Oncol Rep. 2023;47:101155. https:\/\/doi.org\/10.1016\/j.gore.2023.101155.","journal-title":"Gynecol Oncol Rep"},{"key":"754_CR34","unstructured":"Research C for DE and FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FR\u03b1 positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer. FDA; 2024."},{"key":"754_CR35","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","volume":"32","author":"KN Moore","year":"2021","unstructured":"Moore KN, Oza AM, Colombo N, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32:757\u201365. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.017.","journal-title":"Ann Oncol"},{"key":"754_CR36","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN, Angelergues A, Konecny GE, et al. Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023;389:2162\u201374. https:\/\/doi.org\/10.1056\/NEJMoa2309169.","journal-title":"N Engl J Med"},{"key":"754_CR37","unstructured":"Research C for DE and FDA approves mirvetuximab soravtansine-gynx for FR\u03b1 positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. FDA; 2024."},{"key":"754_CR38","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.annonc.2024.11.011","volume":"36","author":"AA Secord","year":"2025","unstructured":"Secord AA, Lewin SN, Murphy CG, et al. The efficacy and safety of mirvetuximab soravtansine in FR\u03b1-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II piccolo trial. Ann Oncol. 2025;36:321\u201330. https:\/\/doi.org\/10.1016\/j.annonc.2024.11.011.","journal-title":"Ann Oncol"},{"key":"754_CR39","doi-asserted-by":"publisher","first-page":"5553","DOI":"10.1200\/JCO.2017.35.15_suppl.5553","volume":"35","author":"DM O\u2019Malley","year":"2017","unstructured":"O\u2019Malley DM, Moore KN, Vergote I, et al. Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer. J Clin Oncol. 2017;35:5553\u20135553. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.5553.","journal-title":"J Clin Oncol"},{"key":"754_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","volume":"170","author":"L Gilbert","year":"2023","unstructured":"Gilbert L, Oaknin A, Matulonis UA, et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2023;170:241\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2023.01.020.","journal-title":"Gynecol Oncol"},{"key":"754_CR41","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT008","volume":"84","author":"RL Porter","year":"2024","unstructured":"Porter RL, Xiong N, Tayob N, et al. Abstract CT008: a phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer. Cancer Res. 2024;84:CT008. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-CT008.","journal-title":"Cancer Res"},{"key":"754_CR42","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1080\/14796694.2024.2372241","volume":"20","author":"DM O\u2019Malley","year":"2024","unstructured":"O\u2019Malley DM, Myers T, Wimberger P, et al. Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FR\u03b1-high platinum-sensitive ovarian cancer. Future Oncol. 2024;20:2423\u201336. https:\/\/doi.org\/10.1080\/14796694.2024.2372241.","journal-title":"Future Oncol"},{"key":"754_CR43","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","volume":"157","author":"DM O\u2019Malley","year":"2020","unstructured":"O\u2019Malley DM, Matulonis UA, Birrer MJ, et al. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020;157:379\u201385. https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.037.","journal-title":"Gynecol Oncol"},{"key":"754_CR44","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ygyno.2024.01.045","volume":"185","author":"DL Richardson","year":"2024","unstructured":"Richardson DL, Moore KN, Vergote I, et al. Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2024;185:186\u201393. https:\/\/doi.org\/10.1016\/j.ygyno.2024.01.045.","journal-title":"Gynecol Oncol"},{"key":"754_CR45","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1073\/pnas.1314118111","volume":"111","author":"N Magnus","year":"2014","unstructured":"Magnus N, Garnier D, Meehan B, et al. Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. Proc Natl Acad Sci USA. 2014;111:3544\u20139. https:\/\/doi.org\/10.1073\/pnas.1314118111.","journal-title":"Proc Natl Acad Sci USA"},{"key":"754_CR46","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.3892\/etm.2018.6723","volume":"16","author":"X Zhao","year":"2018","unstructured":"Zhao X, Cheng C, Gou J, et al. Expression of tissue factor in human cervical carcinoma tissue. Exp Ther Med. 2018;16:4075\u201381. https:\/\/doi.org\/10.3892\/etm.2018.6723.","journal-title":"Exp Ther Med"},{"key":"754_CR47","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","volume":"22","author":"RL Coleman","year":"2021","unstructured":"Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:609\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(21)00056-5.","journal-title":"Lancet Oncol"},{"key":"754_CR48","unstructured":"Research C for DE and FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer. FDA; 2021."},{"key":"754_CR49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","volume":"391","author":"I Vergote","year":"2024","unstructured":"Vergote I, Gonz\u00e1lez-Mart\u00edn A, Fujiwara K, et al. Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N Engl J Med. 2024;391:44\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2313811.","journal-title":"N Engl J Med"},{"key":"754_CR50","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ygyno.2022.02.010","volume":"165","author":"SK Kim","year":"2022","unstructured":"Kim SK, Ursell P, Coleman RL, et al. Mitigation and management strategies for ocular events associated with tisotumab vedotin. Gynecol Oncol. 2022;165:385\u201392. https:\/\/doi.org\/10.1016\/j.ygyno.2022.02.010.","journal-title":"Gynecol Oncol"},{"key":"754_CR51","unstructured":"Research C for DE and FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer. FDA; 2024."},{"key":"754_CR52","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1200\/JCO.23.00720","volume":"41","author":"I Vergote","year":"2023","unstructured":"Vergote I, Van Nieuwenhuysen E, O\u2019Cearbhaill RE, et al. Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205\/GOG-3024\/ENGOT-cx8 study. J Clin Oncol. 2023;41:5536\u201349. https:\/\/doi.org\/10.1200\/JCO.23.00720.","journal-title":"J Clin Oncol"},{"key":"754_CR53","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.3390\/genes13112065","volume":"13","author":"MK Najjar","year":"2022","unstructured":"Najjar MK, Manore SG, Regua AT, Lo H-W. Antibody-drug conjugates for the treatment of HER2-positive breast cancer. Genes. 2022;13:2065. https:\/\/doi.org\/10.3390\/genes13112065.","journal-title":"Genes"},{"key":"754_CR54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","volume":"34","author":"M Yan","year":"2015","unstructured":"Yan M, Schwaederle M, Arguello D, et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34:157\u201364. https:\/\/doi.org\/10.1007\/s10555-015-9552-6.","journal-title":"Cancer Metastasis Rev"},{"key":"754_CR55","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/ajcp\/aqac179","volume":"159","author":"S Shafi","year":"2023","unstructured":"Shafi S, Nitta H, Shah M, et al. HER2 gene protein assay: a robust tool for evaluating HER2 status and intratumoral heterogeneity in endometrial cancers. Am J Clin Pathol. 2023;159:464\u201373. https:\/\/doi.org\/10.1093\/ajcp\/aqac179.","journal-title":"Am J Clin Pathol"},{"key":"754_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygyno.2025.07.024","volume":"201","author":"KE Hacker","year":"2025","unstructured":"Hacker KE, Fleming KA, Gupta M, Pothuri B. HER2 expression in an endometrial cancer cohort. Gynecol Oncol. 2025;201:1\u20136. https:\/\/doi.org\/10.1016\/j.ygyno.2025.07.024.","journal-title":"Gynecol Oncol"},{"key":"754_CR57","doi-asserted-by":"publisher","first-page":"7992","DOI":"10.1038\/s41598-024-57515-y","volume":"14","author":"Y-N Kim","year":"2024","unstructured":"Kim Y-N, Chung YS, Park E, et al. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer. Sci Rep. 2024;14:7992. https:\/\/doi.org\/10.1038\/s41598-024-57515-y.","journal-title":"Sci Rep"},{"key":"754_CR58","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2025.14963","volume":"29","author":"Q Xu","year":"2025","unstructured":"Xu Q, Yin Z, Li Y, et al. Prognostic value of HER2 expression in cervical adenocarcinoma: a retrospective cohort study. Oncol Lett. 2025;29:217. https:\/\/doi.org\/10.3892\/ol.2025.14963.","journal-title":"Oncol Lett"},{"key":"754_CR59","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/GCO.0000000000000599","volume":"32","author":"BK Erickson","year":"2020","unstructured":"Erickson BK, Zeybek B, Santin AD, Fader AN. Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies. Curr Opin Obstet Gynecol. 2020;32:57\u201364. https:\/\/doi.org\/10.1097\/GCO.0000000000000599.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"754_CR60","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22:5097\u2013108. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2822.","journal-title":"Clin Cancer Res"},{"key":"754_CR61","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ygyno.2022.12.018","volume":"170","author":"D Mauricio","year":"2023","unstructured":"Mauricio D, Bellone S, Mutlu L, et al. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2\/neu expression. Gynecol Oncol. 2023;170:38\u201345. https:\/\/doi.org\/10.1016\/j.ygyno.2022.12.018.","journal-title":"Gynecol Oncol"},{"key":"754_CR62","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/modpathol.2011.198","volume":"25","author":"J R\u00fcschoff","year":"2012","unstructured":"R\u00fcschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25:637\u201350. https:\/\/doi.org\/10.1038\/modpathol.2011.198.","journal-title":"Mod Pathol"},{"key":"754_CR63","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1200\/OP.22.00480","volume":"19","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Crossno CL, Gesthalter YB, et al. Real-world perspectives and practices for pneumonitis\/interstitial lung disease associated with Trastuzumab deruxtecan use in human epidermal growth factor receptor 2\u2013expressing metastatic breast cancer. JCO Oncol Pract. 2023;19:539\u201346. https:\/\/doi.org\/10.1200\/OP.22.00480.","journal-title":"JCO Oncol Pract"},{"key":"754_CR64","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.ygyno.2024.07.018","volume":"190","author":"V Makker","year":"2024","unstructured":"Makker V, Oaknin A, Manso L, et al. Efficacy and safety of trastuzumab deruxtecan among patients with HER2-expressing solid tumors: biomarker and subgroup analyses from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study. Gynecol Oncol. 2024;190:S7\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2024.07.018.","journal-title":"Gynecol Oncol"},{"key":"754_CR65","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.22.02558","volume":"41","author":"T Nishikawa","year":"2023","unstructured":"Nishikawa T, Hasegawa K, Matsumoto K, et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2\u2013expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial. J Clin Oncol. 2023;41:2789\u201399. https:\/\/doi.org\/10.1200\/JCO.22.02558.","journal-title":"J Clin Oncol"},{"key":"754_CR66","unstructured":"Research C for DE and FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. FDA; 2024."},{"key":"754_CR67","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.drup.2014.10.002","volume":"17","author":"YG Assaraf","year":"2014","unstructured":"Assaraf YG, Leamon CP, Reddy JA. The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother. 2014;17:89\u201395. https:\/\/doi.org\/10.1016\/j.drup.2014.10.002.","journal-title":"Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother"},{"key":"754_CR68","doi-asserted-by":"publisher","first-page":"S550","DOI":"10.1016\/j.annonc.2024.08.781","volume":"35","author":"EK Lee","year":"2024","unstructured":"Lee EK, Yeku O, Winer I, et al. 719MO A phase I\/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer. Ann Oncol. 2024;35:S550. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.781.","journal-title":"Ann Oncol"},{"key":"754_CR69","doi-asserted-by":"crossref","unstructured":"Lee E. Rinatabart sesutecan (Rina-S) for patients with advanced ovarian cancer: results from dose expansion cohort B1 of a phase 1\/2 study. 2025.","DOI":"10.1016\/j.ygyno.2025.03.100"},{"key":"754_CR70","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1158\/1535-7163.MCT-22-0322","volume":"22","author":"X Li","year":"2023","unstructured":"Li X, Zhou S, Abrahams CL, et al. Discovery of STRO-002, a novel homogeneous ADC targeting folate receptor alpha, for the treatment of ovarian and endometrial cancers. Mol Cancer Ther. 2023;22:155\u201367. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0322.","journal-title":"Mol Cancer Ther"},{"key":"754_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70392","volume":"13","author":"ET Kim","year":"2024","unstructured":"Kim ET, Kim JH, Park EY, et al. The efficacy and safety of folate receptor \u03b1-targeted antibody-drug conjugate therapy in patients with high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers: a systematic review and meta-analysis. Cancer Med. 2024;13:e70392. https:\/\/doi.org\/10.1002\/cam4.70392.","journal-title":"Cancer Med"},{"key":"754_CR72","doi-asserted-by":"publisher","first-page":"5508","DOI":"10.1200\/JCO.2023.41.16_suppl.5508","volume":"41","author":"A Oaknin","year":"2023","unstructured":"Oaknin A, Fari\u00f1as-Madrid L, Garc\u00eda-Duran C, et al. Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolR\u03b1) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolR\u03b1 expression in patients with recurrent epithelial ovarian cancer (OC): update of STRO-002-GM1 phase 1 dose expansion cohort. J Clin Oncol. 2023;41:5508\u20135508. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.5508.","journal-title":"J Clin Oncol"},{"key":"754_CR73","doi-asserted-by":"crossref","unstructured":"Lee J-Y, Oaknin A, Lorusso D, et al. Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: results from the dose-optimization stage of the REFR\u03b1ME-O1 (GOG-3086, ENGOT-79OV, and APGOT-OV9) phase 2\/3 study. Presented at: 2025 SGO Annual Meeting on Women\u2019s Cancer; March 14-17, 2025; Seattle, WA. Abstract 922978.","DOI":"10.1016\/j.ygyno.2025.04.507"},{"key":"754_CR74","unstructured":"Sutro Biopharma, Inc. REFRaME-O1: a phase 2\/3 open-label study evaluating the efficacy and safety of luveltamab tazevibulin (STRO-002) versus investigator\u2019s choice (IC) chemotherapy in women with relapsed platinum-resistant epithelial ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing folate receptor alpha (FOLR1). clinicaltrials.gov; 2024."},{"key":"754_CR75","unstructured":"Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline | Sutro Biopharma, Inc. https:\/\/www.sutrobio.com\/sutro-biopharma-announces-strategic-portfolio-review-resulting-in-the-prioritization-of-its-next-generation-adc-pipeline\/. Accessed 24 Jun 2025."},{"key":"754_CR76","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1158\/1535-7163.MCT-17-1215","volume":"17","author":"X Cheng","year":"2018","unstructured":"Cheng X, Li J, Tanaka K, et al. MORAb-202, an antibody-drug conjugate utilizing humanized anti-human FR\u03b1 farletuzumab and the microtubule-targeting agent eribulin, has potent antitumor activity. Mol Cancer Ther. 2018;17:2665\u201375. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-1215.","journal-title":"Mol Cancer Ther"},{"key":"754_CR77","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1200\/JCO.2022.40.16_suppl.5513","volume":"40","author":"S Nishio","year":"2022","unstructured":"Nishio S, Yunokawa M, Matsumoto K, et al. Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): results from the expansion part of a phase 1 trial. J Clin Oncol. 2022;40:5513\u20135513. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.5513.","journal-title":"J Clin Oncol"},{"key":"754_CR78","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1200\/JCO.2025.43.16_suppl.3023","volume":"43","author":"IL Ray-Coquard","year":"2025","unstructured":"Ray-Coquard IL, O\u2019Malley DM, Pothuri B, et al. Initial results from a first-in-human phase 1 study of LY4170156, an ADC targeting folate receptor alpha (FR\u03b1), in advanced ovarian cancer and other solid tumors. J Clin Oncol. 2025;43:3023\u20133023. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3023.","journal-title":"J Clin Oncol"},{"key":"754_CR79","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/GCO.0000000000000642","volume":"33","author":"J Tymon-Rosario","year":"2021","unstructured":"Tymon-Rosario J, Zeybek B, Santin AD. Novel antibody-drug conjugates: current and future roles in gynecologic oncology. Curr Opin Obstet Gynecol. 2021;33:26\u201333. https:\/\/doi.org\/10.1097\/GCO.0000000000000642.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"754_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105253","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2025","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Janco JMT, Lee J-Y, et al. 127TiP an open-label, randomized, multicenter, phase III study of trastuzumab deruxtecan (T-DXd) with bevacizumab (BEV) vs BEV monotherapy as first-line (1L) maintenance therapy in HER2-expressing ovarian cancer: DESTINY-Ovarian01 (DO 01). ESMO Open. 2025. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105253.","journal-title":"ESMO Open"},{"key":"754_CR81","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1200\/JCO.2023.41.16_suppl.3023","volume":"41","author":"KN Moore","year":"2023","unstructured":"Moore KN, Sabanathan D, Du Y, et al. Safety and efficacy of DB-1303 in patients with advanced\/metastatic solid tumors: a multicenter, open-label, first-in-human, phase 1\/2a study. J Clin Oncol. 2023;41:3023\u20133023. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.3023.","journal-title":"J Clin Oncol"},{"key":"754_CR82","unstructured":"FDA grants fast track designation to DB-1303 for advanced HER2-expressing endometrial cancer. In: Target. Oncol. 2023. https:\/\/www.targetedonc.com\/view\/fda-grants-fast-track-designation-to-db-1303-for-advanced-her2-expressing-endometrial-cancer. Accessed 24 Jun 2025."},{"key":"754_CR83","unstructured":"SE B. BioNTech and dualitybio receive FDA breakthrough therapy designation for antibody-drug conjugate candidate BNT323\/DB-1303 in endometrial cancer. In: GlobeNewswire News Room. 2023. https:\/\/www.globenewswire.com\/news-release\/2023\/12\/21\/2799939\/0\/en\/BioNTech-and-DualityBio-Receive-FDA-Breakthrough-Therapy-Designation-for-Antibody-Drug-Conjugate-Candidate-BNT323-DB-1303-in-Endometrial-Cancer.html. Accessed 24 Jun 2025."},{"key":"754_CR84","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1200\/JCO.2024.42.16_suppl.3031","volume":"42","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang J, Shen L, et al. Evaluation of the safety, pharmacokinetics, and efficacy of JSKN003 in patients with advanced solid tumors: a phase I\/II clinical study. J Clin Oncol. 2024;42:3031\u20133031. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3031.","journal-title":"J Clin Oncol"},{"key":"754_CR85","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbad014.009","volume":"6","author":"P Wang","year":"2023","unstructured":"Wang P, Guo K, Peng J, et al. JSKN003, a novel biparatopic anti-HER2 antibody-drug conjugate, exhibits potent antitumor efficacy. Antibody Therapeutics. 2023;6:tbad014.009. https:\/\/doi.org\/10.1093\/abt\/tbad014.009.","journal-title":"Antibody Therapeutics"},{"key":"754_CR86","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1200\/JCO.2025.43.16_suppl.5565","volume":"43","author":"J Shu","year":"2025","unstructured":"Shu J, Zhu T, Huang Y, et al. IBI354, an anti-HER2 antibody-drug conjugate, in patients with locally advanced unresectable or metastatic ovarian cancers: updated results from a phase I trial. J Clin Oncol. 2025;43:5565\u20135565. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.5565.","journal-title":"J Clin Oncol"},{"key":"754_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(22)01432-9","volume":"166","author":"D Shintani","year":"2022","unstructured":"Shintani D, Hanaoka M, Sato S, et al. Clinical significance of cadherin-6 expression in primary and recurrent epithelial ovarian cancer and its association with outcomes: a potential therapeutic target for epithelial ovarian cancer (206). Gynecol Oncol. 2022;166:S116. https:\/\/doi.org\/10.1016\/S0090-8258(22)01432-9.","journal-title":"Gynecol Oncol"},{"key":"754_CR88","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1002\/1878-0261.12947","volume":"15","author":"RA Bartolom\u00e9","year":"2021","unstructured":"Bartolom\u00e9 RA, Robles J, Martin-Regalado \u00c1, et al. CDH6-activated \u03b1IIb\u03b23 crosstalks with \u03b12\u03b21 to trigger cellular adhesion and invasion in metastatic ovarian and renal cancers. Mol Oncol. 2021;15:1849\u201365. https:\/\/doi.org\/10.1002\/1878-0261.12947.","journal-title":"Mol Oncol"},{"key":"754_CR89","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/j.ygyno.2024.07.017","volume":"190","author":"K Moore","year":"2024","unstructured":"Moore K, Philipovskiy A, Harano K, et al. Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase I study. Gynecol Oncol. 2024;190:S6\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2024.07.017.","journal-title":"Gynecol Oncol"},{"key":"754_CR90","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5625","volume":"42","author":"IL Ray-Coquard","year":"2024","unstructured":"Ray-Coquard IL, Richardson DL, Hasegawa K, et al. REJOICE-Ovarian01: a phase 2\/3 study of raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer (OVC). J Clin Oncol. 2024;42:TPS5625\u2013TPS5625. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS5625.","journal-title":"J Clin Oncol"},{"key":"754_CR91","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000522206","volume":"89","author":"D Dum","year":"2022","unstructured":"Dum D, Taherpour N, Menz A, et al. Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors. Pathobiology. 2022;89:245\u201358. https:\/\/doi.org\/10.1159\/000522206.","journal-title":"Pathobiology"},{"key":"754_CR92","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","volume":"9","author":"DM Goldenberg","year":"2018","unstructured":"Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9:28989\u20139006. https:\/\/doi.org\/10.18632\/oncotarget.25615.","journal-title":"Oncotarget"},{"key":"754_CR93","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3389\/fonc.2020.00118","volume":"10","author":"E Perrone","year":"2020","unstructured":"Perrone E, Lopez S, Zeybek B, et al. Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan (SN-38), in ovarian cancer. Front Oncol. 2020;10:118. https:\/\/doi.org\/10.3389\/fonc.2020.00118.","journal-title":"Front Oncol"},{"key":"754_CR94","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ygyno.2024.07.002","volume":"189","author":"B McNamara","year":"2024","unstructured":"McNamara B, Greenman M, Bellone S, et al. Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma. Gynecol Oncol. 2024;189:16\u201323. https:\/\/doi.org\/10.1016\/j.ygyno.2024.07.002.","journal-title":"Gynecol Oncol"},{"key":"754_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1875","volume":"34","author":"O Marathe","year":"2023","unstructured":"Marathe O, Cheng Y, Spira AI, et al. 689P DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: preliminary clinical results from the phase (Ph) I\/IIa study. Ann Oncol. 2023;34:S480. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1875.","journal-title":"Ann Oncol"},{"key":"754_CR96","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ygyno.2025.03.061","volume":"200","author":"M Rubinstein","year":"2025","unstructured":"Rubinstein M, et al. DB-1305\/BNT325 (a novel TROP-2 ADC) in patients with ovarian cancer: Efficacy and safety data from a phase 1\/2 study. Gynecol Oncol. 2025;200:9\u201310.","journal-title":"Gynecol Oncol"},{"key":"754_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.779","volume":"35","author":"Z Song","year":"2024","unstructured":"Song Z, Chen L, Dang Q, et al. 717MO SHR-A1921 in platinum-resistant ovarian cancer (PROC): data from a first-in-human (FIH) phase I study. Ann Oncol. 2024;35:S549. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.779.","journal-title":"Ann Oncol"},{"key":"754_CR98","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12885-017-3289-2","volume":"17","author":"K Levan","year":"2017","unstructured":"Levan K, Mehryar M, Mateoiu C, et al. Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. BMC Cancer. 2017;17:303. https:\/\/doi.org\/10.1186\/s12885-017-3289-2.","journal-title":"BMC Cancer"},{"key":"754_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.085","volume":"190","author":"D Richardson","year":"2024","unstructured":"Richardson D, Concin N, Hays J, et al. UPLIFT (ENGOT-OV67\/GOG-3048): results from the phase II trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate in platinum-resistant ovarian cancer. Gynecol Oncol. 2024;190:S56. https:\/\/doi.org\/10.1016\/j.ygyno.2024.07.085.","journal-title":"Gynecol Oncol"},{"key":"754_CR100","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1158\/1078-0432.CCR-18-3965","volume":"26","author":"DE Gerber","year":"2020","unstructured":"Gerber DE, Infante JR, Gordon MS, et al. Phase Ia study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin DNIB0600A in patients with non-small cell lung cancer and platinum-resistant ovarian cancer. Clin Cancer Res. 2020;26:364\u201372. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3965.","journal-title":"Clin Cancer Res"},{"key":"754_CR101","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/annonc\/mdy023","volume":"29","author":"S Banerjee","year":"2018","unstructured":"Banerjee S, Oza AM, Birrer MJ, et al. Anti-NaPi2b antibody\u2013drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018;29:917\u201323. https:\/\/doi.org\/10.1093\/annonc\/mdy023.","journal-title":"Ann Oncol"},{"key":"754_CR102","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-2622","volume":"84","author":"S Schmitt","year":"2024","unstructured":"Schmitt S, Mai I, Machui P, et al. Abstract 2622: TUB-040, a novel Napi2b-targeting ADC built with ethynylphosphonamidate conjugation chemistry, demonstrates high and long-lasting anti-tumor efficacy via Topoisomerase-I inhibition and excellent tolerability predictive of a wide therapeutic window in humans. Cancer Res. 2024;84:2622\u20132622. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-2622.","journal-title":"Cancer Res"},{"key":"754_CR103","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Sehouli J, Braicu EI, et al. A phase I dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate (ADC) in patients with platinum-resistant ovarian (PROC) high grade serous carcinoma (HGSC). 2025.","DOI":"10.1016\/j.annonc.2025.09.055"},{"key":"754_CR104","doi-asserted-by":"publisher","first-page":"34103","DOI":"10.18632\/oncotarget.26135","volume":"9","author":"M Quanz","year":"2018","unstructured":"Quanz M, Hagemann UB, Zitzmann-Kolbe S, et al. Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models. Oncotarget. 2018;9:34103\u201321. https:\/\/doi.org\/10.18632\/oncotarget.26135.","journal-title":"Oncotarget"},{"issue":"1","key":"754_CR105","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","volume":"44","author":"R Hassan","year":"2008","unstructured":"Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008;44(1):46\u201353. https:\/\/doi.org\/10.1016\/j.ejca.2007.08.028.","journal-title":"Eur J Cancer"},{"key":"754_CR106","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1136\/ijgc-2022-003927","volume":"33","author":"AD Santin","year":"2023","unstructured":"Santin AD, Vergote I, Gonz\u00e1lez-Mart\u00edn A, et al. Safety and activity of anti-mesothelin antibody\u2013drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study. Int J Gynecol Cancer. 2023;33:562\u201370. https:\/\/doi.org\/10.1136\/ijgc-2022-003927.","journal-title":"Int J Gynecol Cancer"},{"key":"754_CR107","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1158\/1078-0432.CCR-24-3128","volume":"31","author":"HA Alqaisi","year":"2025","unstructured":"Alqaisi HA, Cohn DE, Chern J-Y, et al. Randomized phase II study of bevacizumab with weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant\/refractory high-grade ovarian cancer (NCI trial). Clin Cancer Res. 2025;31:993\u20131001. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3128.","journal-title":"Clin Cancer Res"},{"key":"754_CR108","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.1200\/JCO.2024.42.16_suppl.5551","volume":"42","author":"Y Liu","year":"2024","unstructured":"Liu Y, Li G, Yang R, et al. The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: results from a first-in-human phase 1\/2 study. J Clin Oncol. 2024;42:5551\u20135551. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.5551.","journal-title":"J Clin Oncol"},{"key":"754_CR109","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-22-2981","volume":"29","author":"MSJ McDermott","year":"2023","unstructured":"McDermott MSJ, O\u2019Brien NA, Hoffstrom B, et al. Preclinical efficacy of the antibody-drug conjugate CLDN6\u201323-ADC for the treatment of CLDN6-positive solid tumors. Clin Cancer Res. 2023;29:2131\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2981.","journal-title":"Clin Cancer Res"},{"key":"754_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102748","volume":"12","author":"M Kojima","year":"2020","unstructured":"Kojima M, Sugimoto K, Tanaka M, et al. Prognostic significance of aberrant Claudin-6 expression in endometrial cancer. Cancers (Basel). 2020;12:2748. https:\/\/doi.org\/10.3390\/cancers12102748.","journal-title":"Cancers (Basel)"},{"key":"754_CR111","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1111\/cas.15284","volume":"113","author":"Y Ito","year":"2022","unstructured":"Ito Y, Takasawa A, Takasawa K, et al. Aberrant expression of claudin-6 contributes to malignant potentials and drug resistance of cervical adenocarcinoma. Cancer Sci. 2022;113:1519\u201330. https:\/\/doi.org\/10.1111\/cas.15284.","journal-title":"Cancer Sci"},{"key":"754_CR112","doi-asserted-by":"publisher","first-page":"S551","DOI":"10.1016\/j.annonc.2024.08.783","volume":"35","author":"G Konecny","year":"2024","unstructured":"Konecny G, Hendrickson A, Winterhoff B. Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23, a novel Claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patients with advanced solid tumors. Ann Oncol. 2024;35:S551.","journal-title":"Ann Oncol"},{"key":"754_CR113","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1158\/1078-0432.CCR-23-1079","volume":"30","author":"SB Gitto","year":"2024","unstructured":"Gitto SB, Whicker M, Davies G, et al. A B7\u2013H4 targeting antibody-drug conjugate shows anti-tumor activity in PARPi and platinum resistant cancers with B7\u2013H4 expression. Clin Cancer Res. 2024;30:1567\u201381. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1079.","journal-title":"Clin Cancer Res"},{"key":"754_CR114","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/1535-7163.MCT-22-0786","volume":"22","author":"D Toader","year":"2023","unstructured":"Toader D, Fessler SP, Collins SD, et al. Discovery and preclinical characterization of XMT-1660, an optimized B7\u2013H4-targeted antibody-drug conjugate for the treatment of cancer. Mol Cancer Ther. 2023;22:999\u20131012. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0786.","journal-title":"Mol Cancer Ther"},{"key":"754_CR115","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1200\/JCO.2025.43.16_suppl.3009","volume":"43","author":"EP Hamilton","year":"2025","unstructured":"Hamilton EP, Han HS, Kalinsky K, et al. Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le), a novel B7\u2013H4-directed dolasynthen antibody-drug conjugate. J Clin Oncol. 2025;43:3009\u20133009. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3009.","journal-title":"J Clin Oncol"},{"key":"754_CR116","doi-asserted-by":"publisher","first-page":"S485","DOI":"10.1016\/j.annonc.2024.08.673","volume":"35","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F. Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced\/metastatic solid tumors. Ann Oncol. 2024;35:S485\u20136.","journal-title":"Ann Oncol"},{"key":"754_CR117","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ygyno.2011.02.020","volume":"121","author":"C Th\u00e9riault","year":"2011","unstructured":"Th\u00e9riault C, Pinard M, Comamala M, et al. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol. 2011;121:434\u201343. https:\/\/doi.org\/10.1016\/j.ygyno.2011.02.020.","journal-title":"Gynecol Oncol"},{"key":"754_CR118","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1093\/annonc\/mdw401","volume":"27","author":"JF Liu","year":"2016","unstructured":"Liu JF, Moore KN, Birrer MJ, et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody\u2013drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016;27:2124\u201330. https:\/\/doi.org\/10.1093\/annonc\/mdw401.","journal-title":"Ann Oncol"},{"key":"754_CR119","unstructured":"Inc WT Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company. https:\/\/www.prnewswire.com\/news-releases\/aadi-bioscience-relaunches-as-whitehawk-therapeutics-marking-evolution-into-adc-company-302405009.html. Accessed 1 June 2025."},{"key":"754_CR120","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-438","volume":"83","author":"S Hashimoto","year":"2023","unstructured":"Hashimoto S, Miyamoyo S, Takaiwa A, et al. Abstract 438: antibody drug conjugate using a novel anti-CDCP1 antibody with low hematopoietic stem-cell binding and rapid internalization showed high efficacy for solid cancer. Cancer Res. 2023;83:438. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-438.","journal-title":"Cancer Res"},{"key":"754_CR121","doi-asserted-by":"publisher","first-page":"53","DOI":"10.36401\/JIPO-23-18","volume":"7","author":"K Feustel","year":"2024","unstructured":"Feustel K, Martin J, Falchook GS. B7\u2013H3 inhibitors in oncology clinical trials: a review. J Immunother Precis Oncol. 2024;7:53\u201366. https:\/\/doi.org\/10.36401\/JIPO-23-18.","journal-title":"J Immunother Precis Oncol"},{"key":"754_CR122","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s10517-021-05253-w","volume":"171","author":"OV Kovaleva","year":"2021","unstructured":"Kovaleva OV, Belova TP, Korotkova EA, et al. Soluble B7\u2013H3 in ovarian cancer and its predictive value. Bull Exp Biol Med. 2021;171:472\u20134. https:\/\/doi.org\/10.1007\/s10517-021-05253-w.","journal-title":"Bull Exp Biol Med"},{"key":"754_CR123","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","volume":"15","author":"F Loganzo","year":"2016","unstructured":"Loganzo F, Sung M, Gerber H-P. Mechanisms of resistance to antibody-drug conjugates. Mol Cancer Ther. 2016;15:2825\u201334. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0408.","journal-title":"Mol Cancer Ther"},{"key":"754_CR124","doi-asserted-by":"publisher","first-page":"10211","DOI":"10.3390\/curroncol30120743","volume":"30","author":"MA Fenton","year":"2023","unstructured":"Fenton MA, Tarantino P, Graff SL. Sequencing antibody drug conjugates in breast cancer: exploring future roles. Curr Oncol. 2023;30:10211\u201323. https:\/\/doi.org\/10.3390\/curroncol30120743.","journal-title":"Curr Oncol"},{"key":"754_CR125","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","volume":"14","author":"F Loganzo","year":"2015","unstructured":"Loganzo F, Tan X, Sung M, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015;14:952\u201363. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0862.","journal-title":"Mol Cancer Ther"},{"key":"754_CR126","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/cancers15041278","volume":"15","author":"RO Abelman","year":"2023","unstructured":"Abelman RO, Wu B, Spring LM, et al. Mechanisms of resistance to antibody-drug conjugates. Cancers (Basel). 2023;15:1278. https:\/\/doi.org\/10.3390\/cancers15041278.","journal-title":"Cancers (Basel)"},{"key":"754_CR127","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13058-017-0900-z","volume":"19","author":"T Baldassarre","year":"2017","unstructured":"Baldassarre T, Truesdell P, Craig AW. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers. Breast Cancer Res. 2017;19:110. https:\/\/doi.org\/10.1186\/s13058-017-0900-z.","journal-title":"Breast Cancer Res"},{"key":"754_CR128","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","volume":"17","author":"M Sung","year":"2018","unstructured":"Sung M, Tan X, Lu B, et al. Caveolae-mediated endocytosis as a novel mechanism of resistance to Trastuzumab emtansine (T-DM1). Mol Cancer Ther. 2018;17:243\u201353. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0403.","journal-title":"Mol Cancer Ther"},{"key":"754_CR129","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","volume":"77","author":"C R\u00edos-Luci","year":"2017","unstructured":"R\u00edos-Luci C, Garc\u00eda-Alonso S, D\u00edaz-Rodr\u00edguez E, et al. Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity. Cancer Res. 2017;77:4639\u201351. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-3127.","journal-title":"Cancer Res"},{"key":"754_CR130","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1158\/1535-7163.MCT-17-0296","volume":"17","author":"G Li","year":"2018","unstructured":"Li G, Guo J, Shen B-Q, et al. Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells. Mol Cancer Ther. 2018;17:1441\u201353. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0296.","journal-title":"Mol Cancer Ther"},{"key":"754_CR131","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.2025.43.16_suppl.1041","volume":"43","author":"S Alkassis","year":"2025","unstructured":"Alkassis S, Lipsyc-Sharf M, Traverso C, et al. Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: a comprehensive multi-center study. J Clin Oncol. 2025;43:1041\u20131041. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.1041.","journal-title":"J Clin Oncol"},{"key":"754_CR132","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","volume":"11","author":"JT Coates","year":"2021","unstructured":"Coates JT, Sun S, Leshchiner I, et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to Sacituzumab govitecan in triple-negative breast cancer. Cancer Discov. 2021;11:2436\u201345. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0702.","journal-title":"Cancer Discov"},{"key":"754_CR133","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1158\/1078-0432.CCR-17-0696","volume":"23","author":"M Sabbaghi","year":"2017","unstructured":"Sabbaghi M, Gil-G\u00f3mez G, Guardia C, et al. Defective cyclin B1 induction in Trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer. Clin Cancer Res. 2017;23:7006\u201319. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0696.","journal-title":"Clin Cancer Res"},{"key":"754_CR134","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_431766","author":"L Ascione","year":"2024","unstructured":"Ascione L, Guidi L, Prakash A, et al. Unlocking the potential: biomarkers of response to antibody-drug conjugates. Am Soc Clin Oncol Educ Book. 2024. https:\/\/doi.org\/10.1200\/EDBK_431766.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"754_CR135","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/1535-7163.MCT-23-0482","volume":"23","author":"J Katrini","year":"2024","unstructured":"Katrini J, Boldrini L, Santoro C, et al. Biomarkers for antibody-drug conjugates in solid tumors. Mol Cancer Ther. 2024;23:436\u201346. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0482.","journal-title":"Mol Cancer Ther"},{"key":"754_CR136","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1914510.","journal-title":"N Engl J Med"},{"key":"754_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.008","volume":"102","author":"H-P Gerber","year":"2016","unstructured":"Gerber H-P, Sapra P, Loganzo F, May C. Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect? Biochem Pharmacol. 2016;102:1\u20136. https:\/\/doi.org\/10.1016\/j.bcp.2015.12.008.","journal-title":"Biochem Pharmacol"},{"key":"754_CR138","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac4925","volume":"7","author":"P M\u00fcller","year":"2015","unstructured":"M\u00fcller P, Kreuzaler M, Khan T, et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade. Sci Transl Med. 2015;7:315ra188. https:\/\/doi.org\/10.1126\/scitranslmed.aac4925.","journal-title":"Sci Transl Med"},{"key":"754_CR139","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-1142","volume":"82","author":"Y Wallez","year":"2022","unstructured":"Wallez Y, Proia T, Leo E, et al. Abstract 1142: activity and tolerability of combination of trastuzumab deruxtecan with the next generation PARP1-selective inhibitor AZD5305 in preclinical models. Cancer Res. 2022;82:1142. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-1142.","journal-title":"Cancer Res"},{"key":"754_CR140","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","volume":"14","author":"Y Gu","year":"2024","unstructured":"Gu Y, Wang Z, Wang Y. Bispecific antibody drug conjugates: making 1+1>2. Acta Pharm Sin B. 2024;14:1965\u201386. https:\/\/doi.org\/10.1016\/j.apsb.2024.01.009.","journal-title":"Acta Pharm Sin B"},{"key":"754_CR141","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002015","volume":"9","author":"JJ Luke","year":"2021","unstructured":"Luke JJ, Barlesi F, Chung K, et al. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. 2021;9:e002015. https:\/\/doi.org\/10.1136\/jitc-2020-002015.","journal-title":"J Immunother Cancer"},{"key":"754_CR142","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma Y, Huang Y, Zhao Y, et al. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024;25:901\u201311. https:\/\/doi.org\/10.1016\/S1470-2045(24)00159-1.","journal-title":"Lancet Oncol"},{"key":"754_CR143","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2310890","volume":"16","author":"DL Niquille","year":"2024","unstructured":"Niquille DL, Fitzgerald KM, Gera N. Biparatopic antibodies: therapeutic applications and prospects. MAbs. 2024;16:2310890. https:\/\/doi.org\/10.1080\/19420862.2024.2310890.","journal-title":"MAbs"},{"key":"754_CR144","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2024.42.16_suppl.3038","volume":"42","author":"JJ Park","year":"2024","unstructured":"Park JJ, Gao B, Beecroft C, et al. Safety and efficacy of JSKN003 in patients with advanced\/metastatic solid tumors: a first-in-human, dose-escalation, multicenter, open-label, phase I study. J Clin Oncol. 2024;42:3038\u20133038. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3038.","journal-title":"J Clin Oncol"},{"key":"754_CR145","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/anie.201608292","volume":"56","author":"MR Levengood","year":"2017","unstructured":"Levengood MR, Zhang X, Hunter JH, et al. Orthogonal cysteine protection enables homogeneous multi-drug antibody-drug conjugates. Angew Chem Int Ed Engl. 2017;56:733\u20137. https:\/\/doi.org\/10.1002\/anie.201608292.","journal-title":"Angew Chem Int Ed Engl"},{"key":"754_CR146","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s12282-018-0861-9","volume":"25","author":"H Sakai","year":"2018","unstructured":"Sakai H, Tsurutani J, Iwasa T, et al. HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. Breast Cancer. 2018;25:605\u201313. https:\/\/doi.org\/10.1007\/s12282-018-0861-9.","journal-title":"Breast Cancer"},{"key":"754_CR147","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.1158\/1078-0432.CCR-18-1300","volume":"24","author":"K Kinneer","year":"2018","unstructured":"Kinneer K, Meekin J, Tiberghien AC, et al. SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads. Clin Cancer Res. 2018;24:6570\u201382. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1300.","journal-title":"Clin Cancer Res"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00754-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00754-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00754-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:00:48Z","timestamp":1774418448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00754-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":147,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00754-w","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"3 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Taliya Lantsman declares no conflicts of interest that might be relevant to the contents of this article. Ursula A. Matulonis reports participation in scientific advisory boards (Allarity, NextCure, AbbVie, Immunogen, Profound Bio, Eisai, the Ovarian Cancer Research Alliance, Tango Therapeutics, Novartis, GSK, Daiichi Sankyo, DayOne Bio, and Whitehawk Therapeutics), participation in a data safety-monitoring board (Mural Oncology, Macrogenics, and Symphogen), and consulting (Merck).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable (N\/A).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"No datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"N\/A.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Taliya Lantsman and Ursula A. Matulonis contributed in the drafting and editing of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}